Tartisan will acquire all of the issued and outstanding common shares of Canadian Arrow Mines Limited by way of a court-approved plan of arrangement
Tartisan would issue to Canadian Arrow Mines Limited shareholders one common share of Tartisan for every 17.5 common shares of Canadian Arrow, resulting in the issuance of approximately 8,000,000 common shares of Tartisan
Interesting summary tada, my estimations have come out somewhat similar to yours (not quite as high on the high end) and the company's own NPV chart would suggest the correct neighbourhood (even more when you repeat the exercise for CKD). In any event thanks. I revisited clinical trials.gov which I was led to believe were outside dates and it says final data collection for primary outcome is sept 2018 so I guess we'll know when we know.